Clinical trial · Observational
Study of Blood Immune Cells in Cancer Patients Compared to Controls
Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Tumors have a systemic immune modifying effect. They affect the immune system similarly to states of chronic inflammation and these effects can: * be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means * may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy * are important to monitor if the investigators plan on formulation of systemic immune therapy Thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Carcinoma | Solid Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- cancer patients
- description
- as described patietns with solid cancer about to be treated with anticancer therapies
- label
- control group
- description
- normal populations who domated blood for further use
Primary outcomes (2)
- measure
- changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy
- timeFrame
- 4-2013 24 month
- description
- Hopefully by this time the investigators will be able to see if there are lower zeta chain intracellular expression levels in cancer patients and whether response to therapy enhances recovery of zeta chain
- measure
- levels of zeta chain -cd247 in cancer patients
- timeFrame
- till begining of 2013 ( putative)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * patients with cancer or blood donators agreeing to participate in the trial Exclusion Criteria: * other disease states which may cause chronic inflammation
References
Publications (1)
- BACKGROUNDEzernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, Pikarsky E, Shapira L, Baniyash M. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol. 2006 Oct 1;177(7):4763-72. doi: 10.4049/jimmunol.177.7.4763. PMID 16982917